Literature DB >> 9698051

Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro.

S Giacomelli1, M Palmery, L Romanelli, C Y Cheng, B Silvestrini.   

Abstract

The hallucinogenic effects of lysergic acid diethylamide (LSD) have mainly been attributed to the interaction of this drug with the serotoninergic system, but it seems more likely that they are the result of the complex interactions of the drug with both the serotoninergic and dopaminergic systems. The aim of the present study was to investigate the functional actions of LSD at dopaminergic receptors using prolactin secretion by primary cultures of rat pituitary cells as a model. LSD produced a dose-dependent inhibition of prolactin secretion in vitro with an IC50 at 1.7x10(-9) M. This action was antagonized by spiperone but not by SKF83566 or cyproheptadine, which indicates that LSD has a specific effect on D2 dopaminergic receptors. The maximum inhibition of prolactin secretion achieved by LSD was lower than that by dopamine (60% versus 80%). Moreover, the fact that LSD at 10(-8)-10(-6) M antagonized the inhibitory effect of dopamine (10(-7) M) and bromocriptine (10(-11) M) suggests that LSD acts as a partial agonist at D2 receptors on lactotrophs in vitro. Interestingly, LSD at 10(-13)-10(-10) M, the concentrations which are 10-1000-fold lower than those required to induce direct inhibition on pituitary prolactin secretion, potentiated the dopamine (10(-10)-2.5x10(-9) M)-mediated prolactin secretion by pituitary cells in vitro. These results suggest that LSD not only interacts with dopaminergic receptors but also has a unique capacity for modulating dopaminergic transmission. These findings may offer new insights into the hallucinogenic effect of LSD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698051     DOI: 10.1016/s0024-3205(98)00262-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation.

Authors:  Rainer Kraehenmann; Dan Pokorny; Leonie Vollenweider; Katrin H Preller; Thomas Pokorny; Erich Seifritz; Franz X Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2017-04-07       Impact factor: 4.530

2.  Microarray analysis of mouse brain gene expression following acute ethanol treatment.

Authors:  Julie A Treadwell; Shiva M Singh
Journal:  Neurochem Res       Date:  2004-02       Impact factor: 3.996

3.  Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.

Authors:  Simon B Goldberg; Benjamin Shechet; Christopher R Nicholas; Chi Wing Ng; Geetanjali Deole; Zhuofan Chen; Charles L Raison
Journal:  Psychol Med       Date:  2020-11-04       Impact factor: 7.723

Review 4.  d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.

Authors:  Danilo De Gregorio; Stefano Comai; Luca Posa; Gabriella Gobbi
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

5.  Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.

Authors:  Emma I Kopra; Jason A Ferris; Adam R Winstock; Allan H Young; James J Rucker
Journal:  J Psychopharmacol       Date:  2022-04-07       Impact factor: 4.562

6.  Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies.

Authors:  Stephanie L Borgland; Drew M Neyens
Journal:  J Psychiatry Neurosci       Date:  2022-06-15       Impact factor: 5.699

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.